TITLE

Personalized immunotherapy clinical trials in practice

PUB. DATE
May 2007
SOURCE
Clinical Trials Administrator;May2007, Vol. 5 Issue 5, p51
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article examines some clinical trials where personalized immunotherapy is applied. Argos Therapeutics sponsored three clinical trials that involved a personalized immunotherapy approach. In a trial, a closed-system centrifugation process separates red cells and white blood cells from the monocytes. Participants are monitored in hospital and stay on a leukapheresis machine.
ACCESSION #
24730854

 

Related Articles

  • Personalized immunotherapy research leads to more complex clinical trials.  // Clinical Trials Administrator;May2007, Vol. 5 Issue 5, p49 

    The article focuses on the adoption of personalized immunotherapy approach in clinical trials. Anthony T. Dren, a consulting professor with the Duke University School of Medicine in Durham, North Carolina, claims that personalized medicine is trend of the future. Its advantage is it can lessen...

  • Argos Therapeutics' Arcelis(tm) Immunotherapy for Treatment of HIV Demonstrates Positive Outcomes in Viral Load Control and Favorable Safety and Immunogenicity Profile in Final Analysis of Phase 2a Study.  // Biomedical Market Newsletter;5/5/2011, p880 

    The article reports on the positive outcomes demonstrated by Arcelis immunotherapy for the treatment of HIV, from Argos Therapeutics Inc., the AGS-004. It discusses the study conducted by the company with the AGS-004 in viral load control and favorable safety and immunogenicity profile in a...

  • Improving Personalized Immunotherapies. Nicolette, Charles A. // Drug Discovery & Development;Jun2011 Supplement, Vol. 14, p16 

    The article reports on the development of dendritic cell (DC)-based personalized immunotherapy treatments for infectious and malignant diseases by Argos Therapeutics Inc. The company conducts two Phase 2 clinical trials of AGS-003, the company's Arcelis immunotherapy, in metastatic renal cell...

  • International AIDS Conference.  // BioWorld Today;7/20/2010, Vol. 21 Issue 138, p3 

    This article deals with the interim analysis reported by Argos Therapeutics Inc. at International AIDS Society's 2010 conference from a Phase II data of its Arcelis immunotherapy.

  • 'Ruble' Slippers: Russian Cash in Argos' $42M Phase III Raise. Osborne, Randy // BioWorld Today;8/28/2013, Vol. 24 Issue 165, p1 

    The article reports on the investment received by biotechnology firm Argos Therapeutics from Pharmstandard International SA, the venture arm of Russian pharmaceutical firm Pharmstandard, via a Series E financing deal in August 2013. A total of 42.5 billion dollars has been raised by the deal....

  • 'In a Position to Go It Alone'.  // BioWorld Today;8/28/2013, Vol. 24 Issue 165, p4 

    The article reports on the investment received by biotechnology firm Argos Therapeutics from Pharmstandard International SA, the venture arm of Russian pharmaceutical firm Pharmstandard, via a Series E financing deal in August 2013. A total of 42.5 billion dollars has been raised by the deal....

  • Clinic Roundup.  // BioWorld Today;10/4/2010, Vol. 21 Issue 191, p3 

    This section presents updates on clinical trials including the recruitment of patients for the Phase II study of anti-von Willebrand factor Nanobody by Ablynx NV, interim Phase II trial on AGS-003 plus Sutent from Argos Therapeutics Inc., and the Phase I trial on CK-2017357 drug from...

  • RBC and WBC fatty acid composition following consumption of an omega 3 supplement: Lessons for future clinical trials. Witte, Theodore R.; Salazar, Alexander J.; Ballester, Oscar F.; Hardman, W. Elaine // Lipids in Health & Disease;2010, Vol. 9, p31 

    Background: Results from increasing numbers of in vitro and in vivo studies have demonstrated that omega 3 fatty acids incorporated in cell culture media or in the diet of the animals can suppress the growth of cancers. When human clinical trials are initiated to determine the ability of omega 3...

  • ASCO 2011 Roundup.  // BioWorld Today;6/7/2011, Vol. 22 Issue 109, p3 

    The article states that Argos Therapeutics has reported improve progression-free survival (PFS) in newly diagnosed patients with renal cell carcinoma who were treated with the Arcelis immunotherapy in combination with sunitib, during the 2011 annual meeting of the American Society of Clinical...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics